Alkem Oncology has launched Cetuxa, the world’s first biosimilar of Cetuximab used for the treatment of head and neck cancer. Cetuxa has been researched and manufactured indigenously by Enzene ...

China’s National Medical Products Administration authorized the country’s first cetuximab biosimilar with the approval of Simcere Zaiming’s Enlituo (CMAB-009, cetuximab beta injection) in combination ...

PURPOSESquamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer, with approximately 225,419 new cases with over 125,000 deaths annually in India. This trial compared the ...

The monoclonal antibody cetuximab, while not as effective as cisplatin, is often used as an alternative in these patients. However, there is currently no consensus on the standard of care for this ...

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) have a poor prognosis, particularly those whose disease has progressed on previous platinum ...

Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR.From December 2003 to August 2005, 572 pat ...

We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutati ...

BUFFALO, NY- July 12, 2023 – A new research paper was published in Oncotarget's Volume 14 on July 7, 2023, entitled, “Effectiveness and toxicity of cetuximab with concurrent RT in locally ...

Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. J Clin Oncol. 2025 Jan 22:JCO2401829. doi: 10.1200/JCO-24-01829. Epub ahead of print.